Selfotel

Source: Wikipedia, the free encyclopedia.
Selfotel
Clinical data
Other namesSelfotel
Legal status
Legal status
  • In general: legal
Identifiers
  • (2S,4R)-4-(phosphonomethyl)piperidine-2-carboxylic acid
JSmol)
  • C1CN[C@@H](C[C@@H]1CP(=O)(O)O)C(=O)O
  • InChI=1S/C7H14NO5P/c9-7(10)6-3-5(1-2-8-6)4-14(11,12)13/h5-6,8H,1-4H2,(H,9,10)(H2,11,12,13)/t5-,6+/m1/s1 ☒N
  • Key:LPMRCCNDNGONCD-RITPCOANSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Selfotel (CGS-19755) is a drug which acts as a competitive

neuroprotective effects,[2][3] and it was originally researched for the treatment of stroke,[4] but subsequent animal and human studies showed phencyclidine-like effects,[5][6][7][8] as well as limited efficacy and evidence for possible neurotoxicity under some conditions,[9][10][11] and so clinical development was ultimately discontinued.[12][13]

References

  1. PMID 2899170
    .
  2. PMID 1981269
    .
  3. PMID 2257491
    .
  4. PMID 7709405
    .
  5. PMID 2547931
    .
  6. PMID 2193142
    .
  7. PMID 1432686
    .
  8. PMID 7597121
    .
  9. PMID 10541229
    .
  10. PMID 10657404
    .
  11. S2CID 8793348
    .
  12. S2CID 31477519
    .
  13. PMID 15335108. {{cite book}}: |journal= ignored (help
    )
Retrieved from "https://en.wikipedia.org/w/index.php?title=Selfotel&oldid=1207002651"